Where is this company's market in its cycle, and what does that phase mean for it?
Selvita's outsourced drug discovery business is in the contraction phase of its cycle: commercial revenue in that segment fell to EUR 11.6 million in the first quarter of 2026 from EUR 15.6 million a year earlier, and segment EBITDA dropped to EUR 1.0 million from EUR 1.9 million, a decline the company attributes to a challenging market for outsourced European drug discovery services and to some project delays.
Drug Development moved the other way, with commercial revenue rising 6% year on year in the first quarter of 2026 to EUR 6.2 million, equal to 35% of group commercial revenue. The segment's backlog grew 15% year on year, which the group links to its growth expectation from fast-growing modalities.
What could change its growth trajectory, and what would confirm it?
Selvita expects continued growth from a rising development backlog aligned to fast-growing modalities. Drug Development commercial revenue grew 6% year on year in the first quarter of 2026 to EUR 6.2 million, now 35% of group commercial revenue, while the segment backlog rose 15% year on year, supporting that expectation.
Drug Discovery commercial revenue fell to EUR 11.6 million in the first quarter of 2026 from EUR 15.6 million a year earlier. Full-year 2026 backlog stood at EUR 58.1 million on May 18, 2026, against EUR 58.9 million a year earlier.
Which risks could break the thesis, and what would warn of them?
Selvita's revenue base is exposed to a downturn in the market for outsourced European drug discovery services, and project delays amplify that exposure: Drug Discovery commercial revenue fell to EUR 11.6 million in the first quarter of 2026 from EUR 15.6 million a year earlier, a decline Selvita attributed to the challenging market and to delayed projects.
Full-year 2026 backlog stood at EUR 58.1 million on May 18, 2026, against EUR 58.9 million a year earlier. Drug Development commercial revenue rose 6% year on year to EUR 6.2 million, representing 35% of group commercial revenue, and segment backlog increased 15% year on year.
What does the product do for its buyer, and how is it delivered?
Selvita operates as a contract research organization for discovery-stage work: one provider can carry a drug discovery programme from target validation through preclinical candidate nomination across molecule classes, or take over discrete pieces of it. Its teams work on small molecules, antibodies, targeted protein degraders and other modalities for immunology, oncology and metabolic disease.
Standalone services can be combined as needed, and engagements follow either FTE or fee-for-service models.

Selvita operates as a European contract research organization offering drug discovery and preclinical services to pharmaceutical and biotechnology companies.